Non-infected hemodialysis catheters are associated with increased inflammation compared to arteriovenous fistulas  by Goldstein, Stuart L. et al.
see commentary on page 1025
Non-infected hemodialysis catheters are associated
with increased inflammation compared to
arteriovenous fistulas
Stuart L. Goldstein1, T. Alp Ikizler2, Michael Zappitelli3, Douglas M. Silverstein4 and Juan C. Ayus5
1Baylor College of Medicine, Houston, Texas, USA; 2Vanderbilt University, Nashville, Tennessee, USA; 3McGill University, Montreal,
Quebec, Canada; 4Children’s National Medical Center, Washington, District of Columbia, USA and 5Renal Consultants of Houston,
Houston, Texas, USA
Although hemodialysis catheters predispose to infection
which, in turn, causes inflammation, we studied whether they
induce inflammation independent of infection. We compared
the level of the inflammatory marker C-reactive protein (CRP)
in maintenance hemodialysis patients, comparing those
dialyzed using a non-infected catheter to those using
arteriovenous fistulas. All incident patients had catheters and
fistula placement at dialysis initiation. In 35 patients the
fistulas matured, the catheters were removed and the
patients were evaluated at 6 months (catheter–fistula). These
results were compared to 15 patients in whom the fistula did
not mature and catheter use persisted for 6 months
(catheter–catheter). There was a significant 82% reduction in
the CRP level in the catheter–fistula group but a 16% increase
in the catheter–catheter group at 6 months. The changes in
CRP did not differ by gender, diabetes status, or by race, and
was not correlated with a change in phosphorus, age, or urea
reduction ratio at 1 month following hemodialysis initiation.
Decreased CRP was associated with increased hemoglobin
and albumin. Patients with persistent fistula use from dialysis
initiation through 6 months had consistently low CRP
levels over that time period. Our study shows that catheters
might contribute to increased inflammation independent
of infection, and supports avoidance of catheters and a
timely conversion to fistulas with catheter removal.
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The mortality rate for end-stage renal disease patients,
especially for ones on maintenance hemodialysis (hemo-
dialysis), is six times higher than in the general population.1
Factors associated with poor clinical outcomes in hemo-
dialysis patients include the presence of increased inflamma-
tion.2 The increased levels of markers such as C-reactive
protein (CRP) are associated with increased risk of premature
death and hospitalization.2–4 In addition, chronic inflamma-
tion is highly prevalent in patients receiving hemodialysis5,6
and is linked to poor cardiovascular outcomes.3
Central venous catheters (catheters) are associated with
infection and resultant higher CRP levels, suggesting that
catheters may be an important determinant of the increased
inflammatory response.7–11 Catheter utilization in hemodia-
lysis patients has increased by an alarming rate of 50%
between 1998 and 2004, and data from the United States
Renal Data System indicate that 81% of the patients initiate
hemodialysis through a catheter.1 Recent data show that
changing from an arteriovenous access to catheters is
associated with increased mortality in adult hemodialysis
patients.8 Therefore, avoidance or removal of catheters may
represent an effective strategy to limit the inflammatory
response in hemodialysis patients. In fact, a recent review
suggested that ‘nephrologists are ethically obligated to
explain to patients the harms of tunneled catheters.’7
Although catheters might predispose to infection and result
in inflammation,9 no data exist to assess catheter-induced
inflammation independent of infection.
In this study, incident hemodialysis patients were
evaluated to determine the influence of persistent use of a
non-infected catheter versus use of a matured arteriovenous
fistula (fistulas) on inflammation, using CRP as a marker. We
hypothesized that the presence of persistent catheter use
would be associated with higher CRP when compared with
fistula use, and conversion to a fistula with catheter removal
would lead to a decrease in CRP level. As dialysis vintage is
associated with increased inflammation,5,6,12 we examined
another group of prevalent hemodialysis patients to evaluate
if dialysis vintage could explain potential CRP differences
between patients with a catheter versus a fistula.
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RESULTS
The methodological description for each of the four study
groups discussed below is depicted in Table 1. We observed
no mortality during the 6-month study period in any of the
three longitudinal groups. However, patients were not
followed after the end of the 6-month study period, so
long-term mortality data are not available.
Patients initiating hemodialysis through a catheter
A total of 35 incident patients (mean age 61.5±7.8 years, 18
with diabetes, demographic characteristics shown in Table 2)
initiated hemodialysis with a catheter but then had fistula
maturation and were dialyzed with a fistula by 6 months after
the catheter was removed (catheter–fistula group). Serum
CRP decreased significantly at 6 months compared with the
first month of hemodialysis (Figure 1), while serum albumin
(Alb) and blood hemoglobin (Hb) increased and erythro-
poietin (EPO) doses decreased (all Po0.0001, Table 3). The
erythropoesis resistance index (ERI) also decreased by 69%,
but this was not statistically significant (P¼ 0.016), given the
increased stringency for significance we used to account for
multiple univariate analyses (Po0.01, see Materials and
Methods). Serum phosphorus (Phos) did not differ at
initiation and 6 months. Blood Hb, serum Alb, and CRP
concentrations did not differ between diabetic versus non-
diabetic patients or by gender at either time point (not
shown).
Fifteen incident patients (mean age 63.4±4.6 years, nine
with diabetes) did not have fistula maturation and were
dialyzed with a catheter for the first 6 months of hemodialysis
(catheter–catheter group). In contrast with the catheter–
fistula group, CRP concentrations were no different at
initiation and 6 months (Figure 1). Mean blood Hb levels
increased insignificantly from initiation to 6 months
(10.1±0.5 versus 10.7±0.5 g per 100ml). Furthermore,
EPO dose and ERI did not change at 6 months (Table 3).
Mean blood Hb, serum Alb, and median CRP concentrations
did not differ between diabetic versus non-diabetic patients
or by gender at either time point (not shown). In addition,
no patient had evidence of fistula infection or thrombosis,
which could conceivably lead to elevated CRP levels.
We compared change in CRP (Delta CRP¼ (6 month–1
month)/1 month 100) between the catheter–fistula and
catheter–catheter groups. Delta CRP was 82% (that is, an
82% mean reduction in CRP concentrations by 6 months) in
the catheter–fistula group and þ 16% in the catheter–catheter
group (Po0.001). Delta CRP did not differ by gender (males:
50% versus females: 57%, P¼ 0.65), diabetes status
(no: 57% versus yes: 51%, P¼ 0.64), or by race
(Caucasian: 66% versus African-American: 53% versus
Hispanic: 50%, P¼ 0.74). Delta CRP was not correlated
with Delta Phos (r¼0.12, P¼ 0.42), age (r¼ 0.14,
P¼ 0.35), or urea reduction ratio (URR) at 1 month of
hemodialysis initiation (r¼ 0.01, P¼ 0.92). Decreasing CRP
(a negative Delta CRP) was associated with increases in Hb
(Delta Hb, r¼0.48, P¼ 0.004) and Alb (r¼0.67,
Po0.001).
When using partial correlation analysis (including Delta
CRP, Delta Hb, Delta Alb, and Delta Phos) decreasing CRP
was only significantly associated with increase in Hb (Delta
Hb, partial r¼0.57, Po0.001), and not with Delta Alb





Catheter–fistula (35) Incident Catheters at initiation versus
fistulas at 6 months
Catheter–catheter (15) Incident Catheters at initiation and at
6 months






Table 2 | Demographic data for each of the four study groups
Group (n) Age (years) Vintage (years) M/F Race (n) Diabetic
Catheter–fistula (35) 61.5±7.8 NA 15:20 C(6), AA(17), H(12) 18/35
Catheter–catheter (15) 63.4±4.6 NA 7:8 C(2), AA(8), H(5) 9/15
Fistula-only (23) 50.1±17 NA 11:12 C(11), AA(10), H(2) 6/23
Prevalent (65) 52.6±11.4 3.4±2.2 38:27 C(13), AA(33), H(19) 29/65
AA, African-American; C, Caucasian; H, Hispanic; values mean±s.d.
P<0.001
P<0.17















Figure 1 |C-reactive protein (CRP) levels (mg per 100ml)
decrease significantly in incident maintenance hemodialysis
patients who initially dialyze with a non-infected catheter
but with a fistula at 6 months (Po0.0001). By contrast, no
change in CRP is observed in incident maintenance hemodialysis
patients who initiated dialysis with a catheter and remained with
a catheter at 6 months (P¼ 0.17). CRP concentrations are shown
as median (interquartile range) in the boxes.
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(partial r¼0.23, P¼ 0.12) or Delta Phos (partial r¼0.07,
P¼ 0.66).
In a multiple linear regression analysis, being in the
catheter–fistula group (fistula use by 6 months) was
associated with a decrease in CRP (negative Delta CRP,
Po0.001, model R2¼ 0.88, Po0.001) independent of age,
gender, diabetes status, and race. We repeated this multiple
linear regression analysis, replacing the race variables with
Delta Hb and Delta Alb; being in the catheter–fistula group
remained the only significant independent predictor of
decreasing CRP (Po0.001). Of note, when only the presence
of access change (catheter–fistula versus catheter–catheter)
was included in the regression model, the model R2 was 0.82
(Po0.001); addition of other variables in the model led to a
minimal increase in the model R2 (as high as 0.88),
suggesting that access change at 6 months explained the
majority of the variance in Delta CRP from dialysis initiation
to 6 months.
Out of the entire group, nine patients needed hospitaliza-
tion. Seven of these patients were in the catheter–fistula
group; two patients were in the catheter–catheter group. Six
of the nine patients were female. Six of the nine were
diabetics. Fluid overload was the most common cause of
hospitalization (seven of the nine patients). No patient in
either group was admitted with catheter-related sepsis.
Longitudinal assessment in patients who initiated hemodia-
lysis with a fistula. Twenty-three incident patients (mean age
50.1±17.0 years; six with diabetes, Table 2) were dialyzed
with a fistula alone for the first 6 months. Mean serum Alb
did not differ from initiation to 6 months (3.8±0.5 versus
4.0±0.4mg per 100ml, P¼ 0.18), while blood Hb was
significantly higher at 6 months (10.5±1.5 versus 12.4±1.8 g
per 100ml, Po0.001). EPO dose did not rise significantly
during this period (data not shown). Median (interquartile
range) serum CRP did not differ from dialysis initiation to
6 months (0.5 (0.2, 1.0) mg per 100ml versus 0.7 (0.3, 1.8)
mg per 100ml, P¼ 0.24) and was no different for patients
with versus without diabetes or by gender (not shown).
Sixteen patients had complete data on monthly CRP
concentrations drawn during the first 6 months of dialysis;
using repeated measures analysis of variance (and ln-
transformed CRP levels), there was no significant change in
CRP concentrations at any time point (Huyn-Feldt F-
statistic¼ 1.69, P¼ 0.151) across the 6 months of assessment
(median CRP ranged from 0.5 to 0.8mg per 100ml).
We compared CRP concentrations in this group with CRP
concentrations in the catheter–fistula and catheter–catheter
groups at dialysis initiation and at 6 months. At dialysis
initiation, median CRP levels were significantly lower in the
fistula-only group compared with both the catheter–fistula
and the catheter–catheter groups (Po0.001). At 6 months,
median CRP concentrations for the fistula-only group were
significantly lower than those in the catheter–catheter group
(Po0.01), at which time the catheters was still in place, but
no different compared with the catheter–fistula group
(P40.05), at which time the catheters had been removed.
Cross-sectional study of CRP concentrations and access
type. Sixty-five prevalent hemodialysis patients (mean age
52.6±11.4 years; 29 diabetic, shown in Table 4) had data
available for cross-sectional analysis (44 fistulas, 21 cathe-
ters). Patients dialyzed with a fistula had significantly lower
CRP concentrations than patients dialyzed with a catheter
(Po0.0001, Figure 2), despite the fact that fistula patients
had significantly longer dialysis vintage than catheter patients
Table 3 | Laboratory and CRP values for incident patients
initiating maintenance hemodialysis with a catheter and
fistula use at 6 months (catheter–fistula), persistent
catheter use at 6 months (catheter–catheter) and
fistula-only
Initiation 6 months P-value
Catheter–fistula
Hb (g per 100ml) 10.4±0.5 12.5±0.7 o0.0001
Alb (g per 100ml) 3.4±0.7 4.0±0.2 o0.0001
CRP (mg per 100ml) 4.3 (3.7, 5.0) 0.8 (8.6, 1.1) o0.0001
EPO dose (U/week) 13,425±225 5875±175 o0.01
ERI (U/kg/(Hb)) 537±120 167±75 o0.02
Phosphorus (mg per 100ml) 5.1±1.2 5.0±0.8 0.42
Catheter–catheter
Hb (g per 100ml) 10.1±0.5 10.7±0.5 0.008
Alb (g per 100ml) 3.2±0.2 3.4±0.9 0.47
CRP (mg per 100ml) 4.4 (3.8, 5.0) 4.9 (4.3, 5.9) 0.17
EPO dose (U/week) 14,020±330 15,250±225 0.42
ERI (U/kg/(Hb)) 624±180 675±210 0.38
Phosphorus (mg per 100ml) 5.4±1.0 5.0±0.7 0.20
Fistula-only
Hg (g per 100ml) 10.5±1.5 12.4±1.8 0.0002
Alb (g per 100ml) 3.8±0.5 4.0±0.4 0.18
CRP (mg per 100ml) 0.5 (0.2, 1.0) 0.7 (0.3, 1.8) 0.24*
Alb, albumin; Ca, calcium; CRP, C-reactive protein; ERI, erythropoeisis resistance
index; EPO, erythropoietin; Hb, hemoglobin; IQR, interquartile range; Phos,
phosphorus; URR, urea reduction ratio.
All values mean±s.d. except for CRP: median (IQR).
*P=0.88 for all 6-month CRP comparisons using Kruskal–Wallis test.

















Fistulas (44) 53.4±11.9 4.6±1.8 72.0±3.3 4.0±0.2 12.2±0.4 8.9±0.9 5.0±0.6 0.4 (0.2,0.7)
Catheters (21) 51.0±10.5 1.1±0.8 73.0±4.2 3.4±0.3 10.2±1.0 9.2±0.6 5.2±0.7 3.6 (1.8,6.5)
Alb, albumin; Ca, calcium; CRP, C-reactive protein; Hb, hemoglobin; Phos, phosphorus; URR, urea reduction ratio.
All values mean±s.d. except for CRP: median (IQR).
*Po0.001 for catheters versus fistulas.
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(Table 4). Mean URR did not differ between patients with
either access, but serum Alb and Hb were significantly lower
in catheter patients compared with fistula patients (Table 4).
CRP did not differ by gender, diabetic status, race, or age (all
P40.05, not shown).
In a multiple linear regression analysis, only access type
(use of catheters) was significantly associated with higher
CRP concentrations (Po0.001), independent of age, gender,
diabetes status, race, and dialysis vintage (model R2¼ 0.61,
Po0.001). When we replaced the race variables with URR
and calcium–phosphate product, only access type (catheters
use, Po0.001) was significant in predicting higher CRP
concentrations, independent of age, gender, dialysis vintage,
URR, diabetes status, and calcium–phosphate product
(model R2¼ 0.63, Po0.001). When only access type was
included in the regression model, the model R2 value was still
0.57 (Po0.001).
DISCUSSION
This study indicates that patients who receive dialysis
through a non-infected catheter have an increased CRP
when compared with patients who receive dialysis with a
fistula. This finding was seen both in incident and prevalent
patients and was independent of age, gender, diabetes status,
and dialysis vintage (Tables 3 and 4).
A unique feature of our study was the ability to test our
hypothesis in different groups of incident hemodialysis
patients with varying access type to determine if changing
access will improve markers of inflammation. In incident
patients who initiated dialysis with a non-infected catheter
and had elevated CRP levels, transition to a fistula at 6
months (catheter–fistula group) was probably accompanied
by resolution of the inflammatory state as evidence by an
82% decrease in CRP, improvement of Alb and Hb, and
decreased EPO dose and ERI (Figure 1, Table 3). By contrast,
patients who initiated dialysis with a catheter (catheter–cath-
eter group), which remained in place at 6 months follow-up,
showed no change in these parameters (Figure 1, Table 3).
Multivariate analysis of all incident patients dialyzed initially
with a catheter (the catheter–fistula and catheter–catheter
groups) provided sufficient sample size to reveal catheters to
be associated with increased CRP independent of patient age,
diabetes status, gender, ethnicity, serum Phos, or URR.
Moreover, incident patients who initiated dialysis with a
fistula had significantly lower levels of CRP compared with
incident patients who initiated dialysis with a non-infected
catheter (Table 3). The lower level of CRP in incident patients
with a fistula at initiation remained low for the following 6
months (Table 3).
Finally, a group of prevalent patients dialyzed with a
fistula had significantly lower CRP, higher serum Alb, and
higher Hb levels compared with patients with a catheter
(Figure 2, Table 4). These findings were present despite the
longer dialysis vintage of fistula patients. As patients with a
positive surveillance bacterial culture or fever within 1 week
before analysis were excluded from analysis of this cohort,
infection per se had no impact on the difference in outcome
in incident or prevalent patients using a catheter versus a
fistula.
In the aggregate, these observations are consistent with
our hypothesis that catheter use is associated with increased
inflammatory response and its removal or avoidance could
attenuate the background inflammation commonly observed
in hemodialysis patients. To our knowledge, this is the first
study to systematically show these associations and under-
scores the importance of avoiding catheter use even in the
absence of active infection, and supports the current National
Kidney Foundation-Kidney Disease Outcomes Quality In-
itiative recommendation of a fistula as the preferred vascular
access type.13
Previous studies also show that catheters are associated
with increased risk for all-cause mortality among incident
and prevalent dialysis patients.14–16 Interestingly, in these
studies the increased mortality was seen after adjusting for
infection, with cardiovascular mortality being the most
common cause of death. This study might explain these
findings, as the presence of a non-infected catheter induced a
state of inflammation. Chronic inflammation in dialysis
patients is linked to poor cardiovascular outcomes and is
accompanied by malnutrition, decreased Alb, Hb, and urea
clearance.2,3,17
Removal of infected clotted arteriovenous grafts,18–20
removal of a failed kidney allograft,21 and daily dialysis22
are well-established measures that can ameliorate inflamma-
tion in selected patients. However, there are very few
therapeutic options in the general dialysis population. This
study offers a simple alternative, with a more general
applicability to the dialysis population.
Why did we observe increased CRP in patients with
catheters in the absence of clinical signs of infection? A
prominent role for biofilm may have existed in some of our

















Figure 2 |C-reactive protein (CRP) levels (mg per 100ml) are
significantly lower for prevalent maintenance hemodialysis
patients dialyzed with a fistula versus a non-infected catheter
(Po0.001). CRP concentrations are shown as median
(interquartile range) in the boxes.
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However, a more plausible explanation for the proin-
flammatory state observed in patients with catheters is an
immunological reaction against the catheter material itself. A
comparison of inflammation and infection rates in rabbits
with indwelling catheters composed of silicone, polyur-
ethane, polyvinylchloride, and Teflon, showed that silicone
catheters induced the greatest inflammatory response, either
in the presence or absence of infection.25 In addition,
infection rates were highest in silicone catheters. In a
follow-up study, serum incubated in silicone catheters had
significantly less opsonizing ability compared with sera
incubated in polyurethane or polyvinylchloride catheters,
suggesting that silicone may induce greater inflammation by
excessive complement activation.26
Although it is important in this regard to recognize
that the Tesio catheters (Medcomp, Harleysville, PA) that
were used in this study are made of silicone, the presence of
other catheter materials has also been associated with
increased levels of CRP.11 Furthermore, this study was not
designed to study the effect of different kinds of catheters on
CRP levels.
The strength of our study resides in the large cohort size
without evidence of active infection. Furthermore, using
incident patients with longitudinal follow-up allowed for
patients to serve as their own control. This approach
minimized the potential confounders of the study. Although
this data does not prove causality, it offers the most
supportive evidence at the present time for the role of non-
infected catheters as a contributing factor of inflammation in
dialysis patients.
However, there are also limitations with this study. The
observational design, cross-sectional, or prospective, allows
us only to evaluate associations and does not prove causality.
In contrast, given the obvious ethical considerations, it is not
possible to test these hypotheses through a randomized
clinical trial. The concurrent comparative group allows us to
obtain the most reliable evidence possible. Although we
controlled for patient factors that may influence inflamma-
tion, there may be others unknown to us, which could have
influenced our results. Although all patients were treated
similarly, and we have attempted to avoid any bias in patient
selection, the possibility remains that sicker, frailer, and, by
inference, more inflamed patients are likely to have catheters
and higher CRP levels.
In summary, patients who receive dialysis through a
catheter show significant elevation CRP compared with
patients dialyzed with a fistula. Moreover, inflammation is
attenuated in incident and prevalent patients who change
from a catheter to a fistula. Thus, our data support early and
pre-emptive fistulas placement to avoid the use of catheters
for hemodialysis.
MATERIALS AND METHODS
Study design and setting
This study represents a retrospective cohort analysis of 138 adult
patients receiving maintenance hemodialysis (Table 1). No patient
died during the study period. In addition, all patients in the groups
studied longitudinally completed all 6 months follow-up. Seventy-
three were incident and 65 were prevalent hemodialysis patients.
Incident patients were followed prospectively with longitudinal
analysis of laboratory values. The following were exclusion criteria:
(1) a failed renal allograft in place, (2) a clotted, non-functional
arteriovenous graft in place, (3) patients who were hospitalized for
infection during the month of scheduled blood draw, and (4)
patients with fever in the week before scheduled blood draw (fever
defined as equal to or greater than 37.51C). No patients in this study
were excluded because of these exclusion criteria. Surveillance exit
site cultures were drawn weekly in catheter patients. Exit site and
blood cultures were drawn with CRP assessment. Patients with
positive cultures were excluded from the study. As this was a
retrospective cohort analysis, the study received expedited approval
with a waiver for informed consent from the Baylor College of
Medicine and Vanderbilt School of Medicine Institutional Review
Boards.
Description of study groups
Catheter–fistula group. This group consists of 35 patients who
initiated dialysis with a catheter with a fistula in place. These
patients had fistula maturation with catheter removal and dialysis
with a fistula alone by 6 months. CRP was measured in the first
month of hemodialysis initiation and at 6 months.
Catheter–catheter group. This group consists of 15 patients
initiating dialysis with a catheter with a fistula in place. They had
fistula maturation failure with persistent catheter use by 6 months.
Data from patients with fistula thrombosis were excluded. CRP was
measured in the first month of hemodialysis initiation and at
6 months.
Fistula-only group. This group consists of 23 patients initiat-
ing hemodialysis with a fistula for 6 months. They never had a
catheter in place. All patients had CRP measured in the first and
sixth month of dialysis.
Prevalent maintenance hemodialysis patients
We studied a group of 65 prevalent patients receiving hemodialysis
for at least 2 months.
Vascular access protocol
Fistulas were placed by one vascular surgeon in all incident patients
after venous mapping of both arms to locate the best suitable vessels.
In patients previously followed in the pre-dialysis clinic, fistula
placement was carried out at least 3 months before dialysis
initiation. In a subset of catheter–fistula and catheter–catheter
patients without pre-dialysis care, dialysis was initiated with a
catheter and fistula placement was carried out within 1 month of
dialysis initiation. In catheter patients, all dressings were changed at
each dialysis treatment to inspect for signs of exit site infection. All
exit sites were cleaned with a standard Betadine solution after each
treatment before re-dressing. All catheters had heparin instilled to
prevent thrombosis between hemodialysis treatments; citrate or
antibiotic locks were not used.
Dialysis prescription and patient care
Dialysis treatments used bicarbonate baths and polysulfone
biocompatible membranes (Fresenius USA, Lexington, MA, USA)
(blood flows were 400ml/min and dialysis flows were 800ml/min);
dialysis times and frequency were 240min per session, with a
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frequency of three times per week. Dialysate was assessed monthly
for bacteria and endotoxin levels and were below acceptable limits
throughout the study (o50CFU/ml ando0.99 EU/ml). All patients
with catheters received dialysis with a Tesio catheter system.
Recombinant human erythropoetin and intravenous iron
were prescribed to maintain Hb from 11 to 12 g per 100ml,
transferrin saturation 420% and serum ferritin 4100mg per
100ml per established protocols. Phosphate binders were used to
maintain pre-dialysis serum Phos below 5.5mg per 100ml, and
serum calcium from 8.5 to 9.5mg per 100ml. Vitamin D was
prescribed to maintain intact parathyroid hormone between 150 and
300 pg/ml. Aspirin (81mg) was prescribed daily to all patients
initiating dialysis with a catheter and fistulas together, and in 13% of
patients who initiated dialysis with a fistula alone. All prevalent
patients with a catheter or fistulas were prescribed daily aspirin
(81mg).
Data collection
The main outcome of the study was serum CRP concentration,
measured in all four study groups immediately after the midweek
hemodialysis session, as part of the standard monthly laboratory
assessment. Serum CRP was measured using a nephelometry assay
with an analytical sensitivity of 0.3mg per 100ml and an interassay
variability of 5.9, 3.0, and 2.4% for low, medium, and highest values,
and an intraassay variability of 1.3, 0.4, and 0.3% for low, medium,
and highest values, respectively.
Erythropoietin resistance index, which is another putative
inflammation marker in dialysis patients, was calculated as: weekly
EPO dose (units)/post-dialysis weight (kg)/Hb concentration.19
Other routine laboratory data were collected including URR, Hb,
phosphate, calcium, calcium–phosphate product, and serum Alb
(bromocresyl-green ‘BCG’ method). Demographic data and diabetes
status were recorded.
Statistical analyses and analysis plan. Data were described
using mean±s.d. when the data were normally distributed or by
median (lower, upper interquartile range) when the data were non-
normally distributed. Univariate parametric tests were used
(t-tests, one-way analysis of variance, Pearson’s correlation) to
evaluate normally distributed variable associations and non-
parametric univariate tests (Mann–Whitney, Kruskall–Wallis,
Spearman’s correlation) were used to evaluate non-normally
distributed variables. Categorical variables were compared using
the w2-test. Variables following non-normal distributions
were transformed to their natural logarithm for inclusion in
regression analyses. Regression diagnostics were carried out to
evaluate model assumptions. To account for the number of
univariate tests carried out, we used Po0.01 for statistical
significance to address the potential for a random chance of
detecting significance with a standard P-value o0.05. Analysis was
carried out using STATA 10 (College Station, TX, USA) and SPSS
version 9 (Chicago, IL, USA).
Cross-sectional study of CRP concentrations and access
type. Potential univariate associations between vascular access
type (fistula versus catheter) and CRP, dialysis vintage,
serum calcium and Phos, serum Hb, erythropoeitin doses, ERI,
and serum Alb were evaluated. Potential univariate associations
between CRP and patient age, dialysis vintage and URR were also
evaluated. Multiple linear regression was used to evaluate for an
independent association between access type and CRP concentra-
tions (ln-transformed), controlling for potential confounding
variables.
Comparison of CRP concentrations for catheter versus fistula
use at 6 months
The catheter–fistula and catheter–catheter groups were included in
these analyses. Change in CRP, serum calcium and Phos, blood Hb,
EPO use and Alb at dialysis initiation to 6 months after dialysis
initiation were assessed in both groups. To determine whether
change in access type by 6 months predicted reduction in CRP
concentrations by 6 months, we derived a CRP change score or
Delta CRP: (6 month CRP1 month CRP)/1 month CRP 100. A
negative Delta CRP thus represented a percent reduction in CRP
from dialysis initiation to 6 months. This variable was used as the
outcome in a multiple linear regression analysis, which included
access type at 6 months, gender, age, diabetes status, and race as the
main predictors. We also evaluated the potential effect of change in
Hb and change in Alb on the association between access type and
Delta CRP.
CRP evaluation in patients who initiated hemodialysis with a
fistula. For patients in the fistula-only group, we compared
dialysis initiation and 6-month CRP concentrations, Alb, Hb, and
EPO dose, to evaluate for a significant change in CRP concentration
over time when no catheters was ever used. For patients with
complete data on monthly CRP for 6 months, we used repeated
measures analysis of variance to determine if any change in CRP
occurred over the 6-month study period.
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